SAN DIEGO, Sept. 2, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) clarified today the status and terminology relating to its over-the-counter ("OTC") products, Tolnaftate-D™, Hydrocortisone-D™ and Diphenhydramine-D™.
